Companies / IXC

INVEX THERAPEUTICS LTD

ASX:IXCPharmaceuticals, Biotechnology & Life Sciences
75.2M shares on issueASX (delayed) · snapshot 11 Sept 202676.3M fully diluted+1.5% if every option and right converts$0.12price · delayed$8.6Mmarket cap · indicative

Today’s holders own 98.5% of what they think they own, once every option and right converts.

Minimal
Dilution risk

Runway 4–8 quarters

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway7.2 quarters of funding
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang1.5% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

INVEX THERAPEUTICS LTD has not lodged any share-issuance filings (Appendix 2A) in the past 24 months. The company has made no capital raises in the past 24 months and has no proposed securities issues pending. As of the June 2026 quarter, the company reported A$3.6M in available cash, which represents approximately 7.2 quarters of funding at its recent spending rate. No information on options or rights overhang is available.

AI-generated summary of this page's cited filings · updated 7 Sept 2026
Get told when this changes
Set up alerts
Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.
1.5%
Options & rights overhang
0.0%
In-the-money supply
0
Raises · last 12 months
7.2 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 75.2M per ASX (delayed) (snapshot 11 Sept 2026).
74.75M75.00M75.25M75.50M75.75MDec 24Oct 25Sept 2675.2M

Cash runway

7.2 qtrs
More than four quarters of funding at the recent spend rate.
Funds operations to about Apr 2028 at the reported spend rate.
$3.6M cash after burn from the quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds. Filed with the quarterly report: $4.0M cash at quarter end (item 4.6), 0.0 qtrs of funding on the company’s own estimate. Our figure above carries the filed quarter-end balance forward at the reported spend rate and adds announced raise proceeds.
Free account
14 quarters on record — Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Issuance timeline

Latest 2 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
26 June 20243H · cancellationIXC : ORDINARY FULLY PAID75.2MAppendix 3H
8 Apr 20243H · cancellationIXC : ORDINARY FULLY PAID75.2MAppendix 3H
Free account
2 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Capital raises

No equity raises in the last 24 months.
Free account
Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
1 dated event on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

No Appendix 3B in the last 12 months reports an issue under the 15% placement capacity (as at 2026-09-12).
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.5%
Options & rights overhang · of current shares
0.0%
In-the-money supply · at current price
1.1M
Potential new shares
Dec 2026
Nearest expiry
What a price move would switch on
555k1.1M$0.12 now0.25× today ($0.03) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.06) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.09) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.12) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.14) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.17) — 0 of the priced supply in the money, 0.0% of shares on issue2× today ($0.23) — 0 of the priced supply in the money, 0.0% of shares on issue3× today ($0.35) — 0 of the priced supply in the money, 0.0% of shares on issue5× today ($0.58) — 0 of the priced supply in the money, 0.0% of shares on issue10× today ($1.15) — 1.1M of the priced supply in the money, 1.5% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.12 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 10× today’s price, which takes it to 1.1M (1.5% of shares).

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
CodeSecurityTypeExercise priceExpiryOn issueSource
IXCAIOptionsPrice-triggered$0.681 Dec 20261.1MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

Free account
1 option line on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Director dealings

No director dealing notices (Appendix 3Y) on record.
Free account
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

31 Aug 2026Appendix 4G and Corporate Governance Statement
31 Aug 2026$PAppendix 4E and Annual Report to shareholders
23 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
24 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
23 Apr 2026Invex to Expand Preclinical Research Program
23 Mar 2026Resignation of Joint Company Secretary
17 Feb 2026Results of Meeting
12 Feb 2026$PAppendix 4D and Half Year Report
22 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
16 Jan 2026Notice of Annual General Meeting/Proxy Form
20 Nov 2025Deferral of Annual General Meeting
10 Nov 2025Initial Director's Interest Notice x 2
9 Nov 2025$PReinstatement to Quotation
9 Nov 2025$PBoard and Officer Appointments and Company Address Change
7 Nov 2025Final Director's Interest Notice
7 Nov 2025Final Director's Interest Notice
7 Nov 2025Resignation of Directors, Co Sec and Cancellation of Meeting
7 Nov 2025$PSuspension from Official Quotation
7 Nov 2025$PPause in Trading
3 Nov 2025Exenatide shows additional positive benefits in brain model

Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.